Norman Wolmark

General Surgery

300 Halket Street, UPMC Magee-Womens Hospital, Suite 2601
Pittsburgh, PA 15213

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 137 publications

COMMIT: A Randomized Study of mFOLFOX6/Bevacizumab/Atezolizumab or Atezolizumab Alone as First-Line Treatment of Deficient DNA Mismatch Repair Metastatic Colorectal Cancer.

COMMIT: A Randomized Study of mFOLFOX6/Bevacizumab/Atezolizumab or Atezolizumab Alone as First-Line Treatment of Deficient DNA Mismatch Repair Metastatic Colorectal Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 29, 2026

Lumpectomy Margins and Local Recurrence in DCIS: Results From the NRG Oncology/NSABP B-35 Randomized Clinical Trial.

Lumpectomy Margins and Local Recurrence in DCIS: Results From the NRG Oncology/NSABP B-35 Randomized Clinical Trial.

Journal: JAMA surgery

Published: July 01, 2026

EMPIRE (NSABP FC-13): a biomarker-driven phase II platform trial evaluating cemiplimab-based immunotherapy in microsatellite-stable colorectal cancer with ctDNA-defined minimal residual disease.

EMPIRE (NSABP FC-13): a biomarker-driven phase II platform trial evaluating cemiplimab-based immunotherapy in microsatellite-stable colorectal cancer with ctDNA-defined minimal residual disease.

Journal: Future oncology (London, England)

Published: June 25, 2026

Headwinds in Breast Cancer Research: The Case for Pragmatic Radiotherapy De-escalation Studies.

Headwinds in Breast Cancer Research: The Case for Pragmatic Radiotherapy De-escalation Studies.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 08, 2026

Development and Validation of a Multimodal-Multitask Deep Learning Approach for Estimating Late Distant Recurrence Risk in HR-Positive Early Breast Cancer.

Development and Validation of a Multimodal-Multitask Deep Learning Approach for Estimating Late Distant Recurrence Risk in HR-Positive Early Breast Cancer.

Journal: Cancer research communications

Published: May 20, 2026

Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2- -associated high-risk HER2-negative early breast cancer: Updated results from the OlympiA phase III trial.

Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2- -associated high-risk HER2-negative early breast cancer: Updated results from the OlympiA phase III trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: February 25, 2026

Atezolizumab in early triple-negative breast cancer: the randomized phase 3 NSABP B-59/GeparDouze trial.

Atezolizumab in early triple-negative breast cancer: the randomized phase 3 NSABP B-59/GeparDouze trial.

Journal: Nature medicine

Published: January 20, 2026

Erratum: Machine Learning Predicts Oxaliplatin Benefit in Early Colon Cancer.

Erratum: Machine Learning Predicts Oxaliplatin Benefit in Early Colon Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: October 02, 2025

The Definition of Cure in Colon Cancer: A Pooled Analysis of 15 Randomized Clinical Trials.

The Definition of Cure in Colon Cancer: A Pooled Analysis of 15 Randomized Clinical Trials.

Journal: JAMA oncology

Published: October 02, 2025

AI-powered and manual assessment of tumor-infiltrating lymphocytes in early HER2-positive breast cancer in NSABP B-41.

AI-powered and manual assessment of tumor-infiltrating lymphocytes in early HER2-positive breast cancer in NSABP B-41.

Journal: NPJ breast cancer

Published: September 08, 2025

NRG-BR008/HERO study: a Phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancer.

NRG-BR008/HERO study: a Phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancer.

Journal: Future oncology (London, England)

Published: June 27, 2025

Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy.

Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy.

Journal: The New England journal of medicine

Published: June 04, 2025

Showing 1-12 of 137

Last Updated: 09/26/2026